Pharmaceuticals, Biotechnology and Life Sciences
Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded…
ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) — Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis…
Illustrative image Laboratory, Boehringer Ingelheim This press release is not intended for UK and US media. HERNEXEOS® (zongertinib tablets) has been…
Anavar is a potent anabolic steroid Alternative Pills for men and women that is popular among bodybuilders and athletes in…
– Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protein with pacibekitug across clinically-meaningful subgroups – – Pacibekitug demonstrated…
Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants 93% of MyClimb…
— Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action –DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 31, 2025 (GLOBE…
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke…
V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C)…
Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3In the…